{"url_path":"/sec/plrx/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1746473/0001746473-26-000115-index.html","accession_number":"0001746473-26-000115","cik":"0001746473","ticker":"PLRX","issuer_name":"PLIANT THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1746473/0001746473-26-000115-index.html","primary_entity_key":"0001746473","primary_entity_name":"PLIANT THERAPEUTICS, INC."},"word_count":129,"has_tables":true,"body_markdown":"Item 2.02    Results of Operations and Financial Condition.\n\nOn August 11, 2026, Pliant Therapeutics, Inc. (the \"Company\") issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as [Exhibit 99.1](plrx-2026811xexx991.htm) to this report.\n\nThe information in this Current Report on Form 8-K including the exhibits furnished herewith shall not be deemed \"filed\" for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the \"Exchange Act\") or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing."}